The WACC of Master Pharm SA (MPH.WA) is 9.2%.
Range | Selected | |
Cost of equity | 8.30% - 10.40% | 9.35% |
Tax rate | 19.50% - 20.80% | 20.15% |
Cost of debt | 5.50% - 9.10% | 7.30% |
WACC | 8.1% - 10.3% | 9.2% |
Category | Low | High |
Long-term bond rate | 5.5% | 6.0% |
Equity market risk premium | 6.3% | 7.3% |
Adjusted beta | 0.44 | 0.54 |
Additional risk adjustments | 0.0% | 0.5% |
Cost of equity | 8.30% | 10.40% |
Tax rate | 19.50% | 20.80% |
Debt/Equity ratio | 0.05 | 0.05 |
Cost of debt | 5.50% | 9.10% |
After-tax WACC | 8.1% | 10.3% |
Selected WACC | 9.2% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for MPH.WA:
cost_of_equity (9.35%) = risk_free_rate (5.75%) + equity_risk_premium (6.80%) * adjusted_beta (0.44) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.